PDCD1 and triple-negative breast carcinoma: Lastly, the primary analyses results of a recently completed single arm trial, IMPRIME-1 (NCT02981303) showed that Imprime in combination with an ICI, the anti-programmed cell death protein (PD-1) Ab pembrolizumab in metastatic triple negative breast cancer (TNBC) patients yielded an enhanced 12-month overall survival rate (57.6%) and increased median overall survival (16.4 months).